NEWSROOM

Finding a better way 

By Tyler Francischine - UF Health Writer

As CEO of Morphogenesis Inc., Patricia Lawman, PhD '91, develops novel cell and gene therapies to fight cancer.

Patricia Lawman, PhD ’91, is on a mission to change the future of cancer care. After losing her parents to lung cancer and lymphoma, respectively, she recognized the detrimental impact of radiation and chemotherapy. She knew there must be a way to treat a patient’s cancer without risk of toxicity and other negative side effects.

Setting 2020 ablaze: Meet Tampa Bay's Inno on Fire honorees

By Lauren Coffey - TBBJ & Inno Reporter

50 innovators and companies heating up Tampa Bay's tech and startup scene.

It's fair to say 2020 did not go as expected for most. News of startups shuttering, co-founders leaving and funding drying up began to rack up in March and April. But, so did stories of triumph.

Each year, Tampa Bay Inno honors 50 companies and individuals that are setting the ecosystem on "fire" with major growth.

Bioscience firm makes progress on another kind of vaccine...

Business Observer; by Mark Gordon, Managing Editor

The word vaccine carries heavy weight these days, with its tantalizing possibilities to curb the destruction brought on by a certain C-word. But at Tampa-based bioscience company Morphogenesis, the word vaccine is connected  to a different kind of C-word: cancer.

USF Health and Tampa biotech firm form clinical research partnership

By Lauren Coffey  – TBBJ & Inno Reporter, Tampa Bay Business Journal

The University of South Florida Health Taneja College of Pharmacy is partnering with a Tampa-based biotech firm to help build the talent pipeline and expand research.

USF Health has partnered with Morphogenesis, a biotechnology company developing immunotherapies for cancer patients, on a two-year contract that runs the gamut. 

ImmuneFx Gene Therapy Could be a Game Changer for Cancer Treatment

Grit Daily; by Sarah Marshal

Morphogenesis, a clinical stage company that develops novel cell and gene therapies, based out of Tampa, recently got FDA approval to expand human clinical trials with an innovative cancer therapeutic. Grit Daily interviewed Morphogenesis CEO Dr. Patricia Lawman to get more information about this technology that could potentially be a game-changer in regard to cancer treatment. ImmuneFx is currently being studied in advanced Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) patients.

Tampa's Morphogenesis gets the go-ahead to expand human cancer clinical trials

By Veronica Brezina-Smith  – Reporter, Tampa Bay Business Journal

A Tampa clinical research company working to find a cure for cancer received a green light to expand a trial program.

The Food and Drug Administration has allowed Morphogenesis Inc. to expand its human clinical trials using its ImmuneFx (IFx) cancer vaccine technology for two more types of cancer. 

Tampa could be at the center of finding a cure for cancer

CBS-WTSP-TV Author: Eric Glasser

TAMPA, Fla. — Chances are you or somebody you know has battled cancer. But, did you know a potential treatment for the disease is being developed right here in the Tampa Bay area?

The company behind that promising work, Morphogenesis, announced it’s now expanding human trials of its vaccine called ImmuneFx.

“Yes, it’s very exciting,” said Patricia Lawman, CEO of Morphogenesis.

Tampa company testing cancer vaccine

News | FOX 13 Tampa Bay

TAMPA, Fla. (FOX 13) - A Tampa company says it is testing a vaccine for cancer.

The vaccine does not prevent cancer. Instead, it explores a new way to help the body fight cancer cells.

Scientists at Morphogenesis, Inc. call the "therapeutic vaccine" a simple and safe technology that could help people who already have cancer fight it off.

Morphogenesis to expand clinical trials, physical footprint

By Veronica Brezina-Smith  – Reporter, Tampa Bay Business Journal

The Tampa-based company that’s developing gene and cell therapies to combat cancer is expanding physically and internally.

Morphogenesis, a clinical stage immunotherapy company located in the University Park Center, has been testing its products on various pet animals with 40 different naturally occurring cancers and recently started testing the vaccine on a small group of humans.

Coolest Office Spaces: Morphogenesis creates interactive spaces for big minds

By Pam Huff  – Managing Editor, Tampa Bay Business Journal

Morphogenesis is a clinical stage immunotherapy company headquartered in Tampa. The company’s principal focus is a platform of cancer vaccines that utilize both cell and gene therapies to stimulate the immune system to recognize and combat tumor cells.

Since the company is involved in research, development and manufacturing, a unique, creative environment is critical.

Tampa company focused on cancer treatment launches first human clinical study

By Margie Manning  –  Finance Editor, Tampa Bay Business Journal

Morphogenesis Inc. is launching its first human clinical study for treatment for skin cancer.

It’s an important benchmark for the Tampa company, which raised $16 million earlier this year in a Series A investment round led by entrepreneur and philanthropist Dr. Kiran Patel.

The Phase 1 study is “the biggest milestone so far” for Morphogenesis, said CEO Patricia Lawman, who co-founded the company in 1995.

New HQ puts Tampa immunotherapy company in Moffitt’s backyard

By Margie Manning  –  Finance Editor, Tampa Bay Business Journal

Moffitt Cancer Center has a new neighbor near its McKinley campus.

Morphogenesis Inc., an immunotherapy company that’s just raised $16 million to back its work developing a treatment for cancer, is settling into its new headquarters at 10500 University Center Drive. The 12,000-square-foot headquarters is less than a mile from Moffitt’s outpatient center, where patients in Morphogenesis’ planned clinical trial would be treated, said Patricia Lawman, CEO.